EDIT-401 CRISPR therapy targets LDL reduction; Phase I set for Australia
EDIT-401 in vivo CRISPR aims to reduce LDL cholesterol by upregulating LDLR in the liver. Phase I trials will start in Australia; safety data is expected in Q1 2027, with U.S. entry planned for 2027.
The company said EDIT-401 is an in vivo CRISPR therapy aimed at lowering LDL cholesterol by upregulating LDLR in the liver. S. entry planned for 2027. Cash runway extends into 2028.